Clinical Report: Utilization and Availability of the HPV Vaccine in the United States
Overview
The HPV vaccine is crucial for preventing various cancers linked to HPV, yet vaccination rates have declined since the COVID-19 pandemic. Despite increased availability and insurance coverage, disparities in vaccination and cancer outcomes persist among different racial groups.
Background
Human papillomavirus (HPV) is the most common sexually transmitted infection in the U.S., with significant implications for cancer risk. The HPV vaccine has been shown to prevent several types of cancers, including cervical, anal, and oropharyngeal cancers. Understanding the utilization and barriers to HPV vaccination is essential for improving public health outcomes and reducing cancer incidence.
Data Highlights
Approximately 42.5 million Americans are infected with HPV, with over 49,000 new HPV-related cancer cases reported between 2018 and 2022. Cervical cancer accounts for 90% of HPV-related cases, with significant racial disparities in incidence and mortality rates.
Key Findings
Over 90% of cervical cancer cases are HPV-related, primarily due to strains 16 and 18.
HPV vaccination rates among girls and boys aged 11 to 13 are only 36% and 14%, respectively.
Oropharyngeal cancers are the most common HPV-associated cancers among men, with 70% linked to HPV.
Gardasil®9 is the only HPV vaccine available in the U.S., protecting against 9 strains of HPV.
Racial disparities exist in cervical cancer outcomes, with Black women facing the highest mortality rates despite high screening rates.
Clinical Implications
Healthcare providers should prioritize HPV vaccination in eligible populations to reduce cancer risk. Addressing barriers to vaccination, particularly in racially diverse communities, is essential for improving health equity and outcomes.
Conclusion
The HPV vaccine is a vital tool in cancer prevention, yet efforts must be intensified to improve vaccination rates and address disparities in access and outcomes.
